Results 51 to 60 of about 23,963 (194)

Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION―A 2-Year, Multicenter, Observational, Cohort Study

Brain Sciences, 2022
Multiple sclerosis (MS) patients receiving natalizumab and who are at risk of developing progressive multifocal leukoencephalopathy (PML) often switch to other high-efficacy disease-modifying therapies including fingolimod as a risk mitigation strategy ...
Helmut Butzkueven, Paul S. Giacomini, Stanley Cohan, Tjalf Ziemssen, Daniel Sienkiewicz, Ying Zhang, Yvonne Geissbühler, Diego Silva, Davorka Tomic, Harald Kropshofer, Maria Trojano   +10 more
doaj   +1 more source

Stimulation of S1PR5 with A-971432, a selective agonist, preserves blood-brain barrier integrity and exerts therapeutic effect in an animal model of Huntington's disease [PDF]

, 2018
Huntington's disease (HD) is themost common neurodegenerative disorder for which no effective cure is yet available. Although several agents have been identified to provide benefits so far, the number of therapeutic options remains limited with only ...
Amico, Enrico, Buttari, Fabio, Capocci, Luca, Castaldo, Salvatore, Di Pardo, Alba, Giovannelli, Alfredo, Madonna, Michele, Maglione, Vittorio, Marracino, Federico, Pepe, Giuseppe, van Bergeijk, Jeroen, van der Kam, Elizabeth   +11 more
core   +1 more source

Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants

Annals of Clinical and Translational Neurology, EarlyView.
Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants. ABSTRACT Objective Return of disease activity is expected when patients discontinue disease‐modifying therapy (DMT) for multiple sclerosis (MS). Some MS DMTs are associated with higher‐than‐expected disease activity (rebound) after discontinuation.
Ralf Gold, Krzysztof W. Selmaj, Regina Berkovich, Jeffrey A. Cohen, Giancarlo Comi, Eva K. Havrdová, James K. Sheffield, Hetal Desai, Chun‐Yen Cheng, Jon V. Riolo, Andrew Thorpe, Erik DeBoer, Bruce A. C. Cree   +12 more
wiley   +1 more source

Non-traumatic Acute Epidural Hematoma in Multiple Sclerosis Treated With Fingolimod

Frontiers in Neurology, 2019
Fingolimod acts as a functional antagonist of the sphingosine-1-phosphate receptor and is widely used for relapsing-remitting multiple sclerosis (MS).
Ryoko Fukai, Keita Takahashi, Hiroyuki Abe, Yuichi Higashiyama, Hiroshi Doi, Hideyuki Takeuchi, Fumiaki Tanaka   +6 more
doaj   +1 more source

A experiência da vida real com complicações cardiovasculares na primeira dose de fingolimode [PDF]

, 2014
Fingolimod is a new and efficient treatment for multiple sclerosis (MS). The drug administration requires special attention to the first dose, since cardiovascular adverse events can be observed during the initial six hours of fingolimod ingestion.
Arruda, Christian Cardoso, Arruda, Walter Oleschko, Brooks, Joseph Bruno Bidin, Damasceno, Alfredo, Damasceno, Carlos Augusto de Albuquerque, Finkelsztejn, Alessandro, Finkelsztejn, Juliana, Fragoso, Yara Dadalti, Gama, Paulo Diniz da, Giacomo, Maria Cristina Brandão, Gomes, Sidney, Goncalves, Marcus Vinicius Magno, Matta, Andre Palma da Cunha, Morais, Marilia Manprim de, Oliveira, Enedina Maria Lobato de, Ribeiro, Yuna, Sato, Henry Koiti, Tauil, Carlos Bernardo   +17 more
core   +4 more sources

Engineered ETS1‐Nanoconjugate Restores Immune Homeostasis through Dual Immune‐Vascular Modulation in Relapsing and Progressive Multiple Sclerosis

Advanced Healthcare Materials, EarlyView.
The biomimetic nanoplatform IMNP (ETS1 pDNA/PBAE@ITP‐MM) undergoes targeted disassembly at inflammatory vascular sites to release the ETS1 plasmid (pETS1). This release initiates a cascade of effects that inhibit pathogenic pathways and support immune homeostasis. (Abbreviations: EndMT, endothelial‐to‐mesenchymal transition; EC, endothelial cell; TC, T
Feng Zhang, Si‐Bo Yang, Yan Luo, Xiao‐Di Sun, Bo‐Hao Chang, Da‐Qiang Zhou, Jun‐Jie Jiang, Ya‐Nan Li, Jie‐Hong Wu, Hui‐Juan Jin, Hang Yang, Hang Hu, Yi‐Fan Zhou, Bo Hu   +13 more
wiley   +1 more source

Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis [PDF]

, 2015
Different therapeutic strategies are available for the treatment of people with relapsing-remitting multiple sclerosis (RRMS), including immunomodulators, immunosuppressants and biologics.
D'Amico, Roberto, Del Giovane, Cinzia, Filippini, Graziella, Salanti, Georgia, Tramacere, Irene   +4 more
core   +1 more source

Evaluation of the Dual Impact of Nanotechnologies on Health and Environment Through Alternative Bridging Models

Advanced Healthcare Materials, EarlyView.
This review explores how alternative invertebrate and small‐vertebrate models advance the evaluation of nanomaterials across medicine and environmental science. By bridging cellular and organismal levels, these models enable integrated assessment of toxicity, biodistribution, and therapeutic performance.
Marie Celine Lefevre, Margherita Bernardeschi, Matteo Battaglini, Gianni Ciofani   +3 more
wiley   +1 more source

Assessing the potential impact of non-proprietary drug copies on quality of medicine and treatment in patients with relapsing multiple sclerosis: the experience with fingolimod

Drug Design, Development and Therapy, 2014
Jorge Correale,1 Erwin Chiquete,2 Snezana Milojevic,3 Nadina Frider,3 Imre Bajusz31Raúl Carrea Institute for Neurological Research, Foundation for the Fight against Infant Neurological Illnesses, Buenos Aires, Argentina; 2Department of Neurology ...
Correale J, Chiquete E, Milojevic S, Frider N, Bajusz I   +4 more
doaj  

Initiating oral fingolimod treatment in patients with multiple sclerosis

Therapeutic Advances in Neurological Disorders, 2013
Fingolimod, the first oral disease-modifying therapy (DMT) approved for the treatment of multiple sclerosis (MS) and the only sphingosine 1-phosphate receptor modulator approved for any disease state, represents an important addition to the expanding DMT
Barry A. Singer
doaj   +1 more source